Carasent AB (CARA) Price & Analysis

Compare

0 Followers

CARA Stock Chart & Stats

kr29.00

-kr0.28(-1.22%)

At close: Mar 05 4:00 PM EST

kr29.00

-kr0.28(-1.22%)

Day’s Range― - ―

52-Week Rangekr19.60 - kr31.25

Previous CloseN/A

Volume42.56K

Average Volume (3M)175.33K

Market Cap

kr1.61B

Enterprise Valuekr1.54B

Total Cash (Recent Filing)kr139.48M

Total Debt (Recent Filing)kr31.94M

Price to Earnings (P/E)47.1

Beta0.04

Next Earnings

Apr 14, 2026

EPS Estimate

0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.41

Shares Outstanding72,324,780

10 Day Avg. Volume229,351

30 Day Avg. Volume175,329

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)2.36

Price to Sales (P/S)5.54

P/FCF Ratio-4.00K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetDeclining absolute debt and low debt-to-equity (low single digits) provide structural financial flexibility. A conservatively financed balance sheet reduces refinancing risk, supports investment or M&A optionality, and cushions the company through industry cycles over the next several quarters.

Revenue Growth And Profitability TurnaroundSustained top-line expansion alongside a move to positive net income and EBIT in 2025 indicates improving business economics. If maintained, higher scale and restored profitability can fund R&D and customer success, strengthening market position in healthcare tech over the medium term.

Improving Operating Cash GenerationRising operating cash flow shows core software/subscription operations are generating more cash, supporting recurring revenue durability. Strong OCF helps fund working capital and investments internally, reducing reliance on external financing over the next several quarters.

Bears Say

Persistently Weak Free Cash FlowChronic negative free cash flow constrains the company’s ability to self-fund growth, dividends, or bolt-on acquisitions. Even with improving OCF, ongoing capex or working-capital demands that keep FCF negative limit strategic flexibility and raise execution risk over the medium term.

Earnings Volatility And Recent LossesLarge swings from losses to profit indicate earnings are sensitive to operational or one-time factors. This volatility reduces visibility for reinvestment planning and raises the risk that margins could revert, making durable margin expansion less certain in the coming quarters.

Balance Sheet ContractionDeclining equity and assets point to a shrinking capital base or asset sales, which can limit scale and resilience. Persistent balance-sheet contraction could impair ability to absorb shocks or finance growth organically, increasing dependence on external capital.

Carasent AB News

Carasent Boosts Growth and Swings to Profit in 2025

An update from Carasent AB ( ($SE:CARA) ) is now available. Carasent AB reported strong full-year 2025 results,...

11d ago

CARA

Carasent to Present Q4 2025 Interim Results on 12 February

The latest announcement is out from Carasent AB ( ($SE:CARA) ). Carasent AB, a Swedish healthcare technology company...

14d ago

CARA

Carasent Nomination Committee Proposes Unchanged Board Line-Up for 2026 AGM

The latest update is out from Carasent AB ( ($SE:CARA) ). Carasent AB’s nomination committee has presented its...

17d ago

CARA

Carasent AB Increases Shareholding to Over 5%

Carasent AB ( ($SE:CARA) ) has issued an update. Carasent AB, a company involved in share trading and...

2M ago

CARA

Carasent AB Appoints 2026 Nomination Committee

An update from Carasent AB ( ($SE:CARA) ) is now available. Carasent AB has announced the appointment of...

4M ago

CARA

Carasent AB Launches SEK 150 Million Share Buy-Back Program

An update from Carasent AB ( ($SE:CARA) ) is now available. Carasent AB has announced a SEK 150...

8M ago

CARA

Carasent AB Revises 2025 Financial Targets Amid Organizational Changes

Carasent AB ( ($SE:CARA) ) just unveiled an update. Carasent AB has revised its financial targets for 2025,...

8M ago

CARA

Carasent AB to Present Q2 2025 Financial Results

An announcement from Carasent AB ( ($SE:CARA) ) is now available. Carasent AB has announced that it will...

8M ago

CARA

CARA FAQ

What was Carasent AB’s price range in the past 12 months?

Carasent AB lowest stock price was kr19.60 and its highest was kr31.25 in the past 12 months.

What is Carasent AB’s market cap?

Carasent AB’s market cap is kr1.61B.

When is Carasent AB’s upcoming earnings report date?

Carasent AB’s upcoming earnings report date is Apr 14, 2026 which is in 50 days.

How were Carasent AB’s earnings last quarter?

Carasent AB released its earnings results on Feb 12, 2026. The company reported kr0.41 earnings per share for the quarter, beating the consensus estimate of kr0.075 by kr0.335.

Is Carasent AB overvalued?

According to Wall Street analysts Carasent AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Carasent AB pay dividends?

Carasent AB pays a Notavailable dividend of kr1.84 which represents an annual dividend yield of N/A. See more information on Carasent AB dividends here

What is Carasent AB’s EPS estimate?

Carasent AB’s EPS estimate is 0.08.

How many shares outstanding does Carasent AB have?

Carasent AB has 72,324,780 shares outstanding.

What happened to Carasent AB’s price movement after its last earnings report?

Carasent AB reported an EPS of kr0.41 in its last earnings report, beating expectations of kr0.075. Following the earnings report the stock price went up 1.739%.

Which hedge fund is a major shareholder of Carasent AB?

Currently, no hedge funds are holding shares in SE:CARA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Carasent AB

Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webdoc X, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.